Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 25, 2025
NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel inhibition treatment in neuromuscular disease model
GlobeNewswire
·
March 25, 2025
Company presented clinical and preclinical data at the MDA Conference last week in Dallas, Texas Oral presentation included data from MuSK-MG rat model depicting increases in muscle function and improvements in the structural integrity of the neuromuscular …
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
GlobeNewswire
·
March 25, 2025
Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan Tumor response models for novel compounds represent true drug discovery using Predictive's active …
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
GlobeNewswire
·
March 25, 2025
Demonstrated substantial and statistically significant improvement in ADHD symptoms as measured by the AISRS total score compared to placebo (p=0.039, primary endpoint, 150 mg solriamfetol) Statistically significant reduction in overall ADHD disease …
Sanara MedTech Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (Unaudited)
GlobeNewswire
·
March 25, 2025
Q4 Net Revenue Increased 49% Year-Over-Year; 2024 Net Revenue Increased 33% Year-Over-Year FORT WORTH, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company …
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
GlobeNewswire
·
March 25, 2025
Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis Continued demonstration of favorable tolerability profile generally consistent with previously reported data; …
Teleflex Announces Updated Clinical Study Data Presented at the European Association of Urology (EAU) Congress
GlobeNewswire
·
March 25, 2025
WAYNE, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that new findings from the CLEAR study were presented at the 40th Annual European Association of Urology ( …
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 25, 2025
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026 4WARD trial protocol refined, increasing confidence in successful outcome 2024 …
Alviona who wants to be my Alviona Avis partner Weight Loss Results
GlobeNewswire
·
March 25, 2025
ALMERE, Netherlands, March 25, 2025 (GLOBE NEWSWIRE) -- The foundation of weight reduction therapy, which was discovered a century ago, is the utilization of the body's innate mechanism for energy production. Due to its propensity to produce quick and long …
Philips demonstrates innovation power, topping European Patent Office Medtech filings in 2024
GlobeNewswire
·
March 25, 2025
March 25, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that in 2024 it was the leading applicant in the field of medical technology at the European Patent Office (EPO), filing …
Personalized Cancer Vaccines Clinical Trials Market Opportunity Technology Platform Insight
GlobeNewswire
·
March 25, 2025
Delhi, March 25, 2025 (GLOBE NEWSWIRE) -- Global Personalized Cancer Vaccine Market Opportunity …
Allegro’s injectable osteoarthritis treatment generates positive safety results in preclinical studies
GlobeNewswire
·
March 25, 2025
Microparticle hydrogel shows clean systemic toxicity profile over 4 weeks and 13 weeks Treatment designed to restore shock-absorbing capacities of joints in osteoarthritis Allegro plans to start pivotal clinical trials in osteoarthritis patients in 2025 …
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
GlobeNewswire
·
March 25, 2025
- Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales -Deal underscores the commercial …
Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
GlobeNewswire
·
March 25, 2025
Saint-Herblain (France), March 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 24, 2025, of its 2024 Universal Registration Document (URD) with the French Financial Markets …
Valneva annonce le dépôt de son Document d’Enregistrement Universel 2024 et de son rapport annuel américain « Form 20-F »
GlobeNewswire
·
March 25, 2025
Saint-Herblain (France), 25 mars 2025 – Valneva SE (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui le dépôt, le 24 mars 2025, de son Document d’enregistrement universel 2024 auprès de l’Autorité des …
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
GlobeNewswire
·
March 25, 2025
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple …
Communiqué de presse : Examen prioritaire accordé aux États-Unis à la soumission réglementaire relative au tolebrutinib pour le traitement de la sclérose en plaques
GlobeNewswire
·
March 25, 2025
Examen prioritaire accordé aux États-Unis à la soumission réglementaire relative au tolebrutinib pour le traitement de la sclérose en plaques S’il est approuvé, le tolebrutinib sera le premier et le seul inhibiteur de la BTK à pénétration cérébrale pour le …
NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel inhibition treatment in neuromuscular disease model
GlobeNewswire
·
March 25, 2025
Company presented clinical and preclinical data at the MDA Conference last week in Dallas, Texas Oral presentation included data from MuSK-MG rat model depicting increases in muscle function and improvements in the structural integrity of the neuromuscular …
更正 – 助力生物科技公司的全球扩展: Avance Clinical 艾凡思生技公司与台湾四家一流的临床中心签署战略合作协议
GlobeNewswire
·
March 25, 2025
台湾台北和澳大利亚阿德莱德, March 25, 2025 (GLOBE NEWSWIRE) -- 全球领先的全方位服务合同研究组织 (CRO) Avance Clinical 专注于高质量且灵活的临床生物科技研究服务。本周，Avance Clinical 欣然宣布与台湾重要临床试验机构签署了四项谅解备忘录 (MOU)。 这些新建立的合作伙伴关系标志着向台湾进行的战略扩张，再一次印证 Avance Clinical 为美国生物科技公司提供亚太地区高质量临床研究解决方案的决心。 Avance Clinical …
更正 – 助力生物科技公司的全球擴展: Avance Clinical 艾凡思生技公司與四家台灣頂尖醫療中心簽署合作備忘錄
GlobeNewswire
·
March 25, 2025
台北，台灣及阿德萊德，澳洲, March 25, 2025 (GLOBE NEWSWIRE) -- Avance Clinical 是一家全球頂尖的全方位服務受託研究機構 (CRO)，專門提供優質而靈活的臨床生物科技研究服務。該公司欣然宣佈本週與四個台灣主要的臨床試驗單位簽署了諒解備忘錄 (MOU)。 這些新的合作夥伴關係標誌著 Avance Clinical 在台灣的策略擴展，鞏固了該公司致力為美國生物科技公司在亞太區提供優質臨床研究解決方案的承諾。 Avance Clinical 行政總裁 Yvonne …
CORRECTION – Global Reach for Biotechs: Avance Clinical Secures MOUs with Four Premier Taiwanese Trial Sites
GlobeNewswire
·
March 25, 2025
TAIPEI, Taiwan and ADELAIDE, Australia, March 25, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, a leading full-service global Contract Research Organization (CRO) specializing in high-quality, agile clinical biotech research services, is pleased to announce …